Acasti Pharma Inc
For the period ended Mar 31, 2024. Filed Jun 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Jun 21, 2024
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year ended March 31, 2024 | Year ended March 31, 2023 | |
|---|---|---|
| (Expressed in thousands) | $ | $ |
| Cash flows used in operating activities: | ||
| Net loss | (12,853) | (42,429) |
| Adjustments: | ||
| Depreciation of equipment | 11 | 124 |
| Gain on sale of equipment | (59) | — |
| Impairment of intangible assets | — | 28,682 |
| Impairment of goodwill | — | 4,826 |
| Impairment of assets held for sale | — | 400 |
| Stock-based compensation | 913 | 1,811 |
| Change in fair value of warrant liabilities | 2,728 | (10) |
| Deferred income tax benefit | (1,832) | (9,542) |
| Unrealized foreign exchange (gain) loss | — | 5 |
| Loss on disposal | 39 | 39 |
| Changes in operating assets and liabilities: | ||
| Receivables | 80 | (302) |
| Prepaid expenses | 315 | 72 |
| Trade and other payables | (1,652) | 411 |
| Operating lease right of use asset | (23) | — |
| Net cash used in operating activities | (12,333) | (15,913) |
| Cash flows from investing activities: | ||
| Purchase of equipment | (22) | (17) |
| Proceeds from sale of equipment | 111 | — |
| Purchase of short-term investments | (6,554) | (5,015) |
| Maturity of short-term investments | 6,569 | 18,185 |
| Net cash provided by investing activities | 104 | 13,153 |
| Cash flows from financing activities: | ||
| Net proceeds from issuance of common shares and warrants from private placement | 7,338 | — |
| Proceeds from issuance of common shares from exercise of stock options | 21 | — |
| Net proceeds from shares issued under the at-the-market (ATM) program | — | 304 |
| Net cash provided by financing activities | 7,359 | 304 |
| Effect of exchange rate fluctuations on cash and cash equivalents | — | (8) |
| Net decrease in cash and cash equivalents | (4,870) | (2,464) |
| Cash and cash equivalents, beginning of year | 27,875 | 30,339 |
| Cash and cash equivalents, end of year | 23,005 | 27,875 |
| Cash and cash equivalents are comprised of: | ||
| Cash | 3,280 | 17,803 |
| Cash equivalents | 19,725 | 10,072 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.